• Explore /
  • Poster
  • / A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613.

A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613.

Abstract Poster

Authors

Kanwal Raghav

Kanwal Pratap Singh Raghav

University of Texas MD Anderson Cancer Center, Houston, TX;

Kanwal Pratap Singh Raghav , Katherine A Guthrie , Scott Kopetz , Benjamin R. Tan , Crystal S. Denlinger , Marwan Fakih , Michael J. Overman , Arvind Dasari , Larry R. Corum , Lee G. Hicks , Mital Patel , Benjamin T Esparaz , Syed Mohammad Ali Kazmi , Nitya Alluri , Sarah Colby , Sepideh Gholami , Philip Jordan Gold , E. Gabriela Chiorean , Howard S. Hochster , Philip Agop Philip

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03365882

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 140)

DOI

10.1200/JCO.2023.41.4_suppl.140

Abstract #

140

Poster Bd #

G18

Abstract Disclosures

Similar Posters

First Author: Kanwal Pratap Singh Raghav

First Author: Ryul Kim

First Author: Sadakatsu Ikeda

First Author: Sayeh Moazami Lavasani